Daiichi Pharmaceutical Receives Import Approval for Ultrasound Contrast Medium Sonazoid.Tokyo, Japan, Oct 26, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Japan's Ministry of Labour, Health and Welfare ttoday granted Daiichi Pharmaceutical approval for the ultrasound contrast medium Sonazoid for Injection, a worldwide first. Sonazoid, which is developed in close collaboration with GE Healthcare GE Healthcare is a $18 billion (USD) unit of General Electric (GE). It employs more than 46,000 people worldwide and is headquartered in Chalfont St. Giles, Buckinghamshire, United Kingdom. GE Healthcare is the first GE business segment headquartered outside the United States. , the licensor, is a minimally invasive contrast medium characterized by prolonged ability to maintain its contrasting attributes. Sonazoid promises to contribute to improving differential and presence diagnosis in diagnosing lesions associated with hepatic hepatic /he·pat·ic/ (he-pat´ik) pertaining to the liver. he·pat·ic adj. 1. Of, relating to, or resembling the liver. 2. Acting on or occurring in the liver. n. tumors as well as assessing the effectiveness of local treatment and post-treatment follow-ups in liver cancer Liver Cancer Definition Liver cancer is a relatively rare form of cancer but has a high mortality rate. Liver cancers can be classified into two types. patients. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion